000 01476 a2200361 4500
005 20250516184522.0
264 0 _c20140408
008 201404s 0 0 eng d
022 _a1532-6535
024 7 _a10.1038/clpt.2013.234
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aTurner, R M
245 0 0 _aCardiovascular pharmacogenomics: expectations and practical benefits.
_h[electronic resource]
260 _bClinical pharmacology and therapeutics
_cMar 2014
300 _a281-93 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAdrenergic beta-Antagonists
_xadministration & dosage
650 0 4 _aAnimals
650 0 4 _aAnti-Arrhythmia Agents
_xadministration & dosage
650 0 4 _aAnticoagulants
_xadministration & dosage
650 0 4 _aCardiovascular Diseases
_xdrug therapy
650 0 4 _aClopidogrel
650 0 4 _aHumans
650 0 4 _aHydroxymethylglutaryl-CoA Reductase Inhibitors
_xadministration & dosage
650 0 4 _aPharmacogenetics
_xtrends
650 0 4 _aPlatelet Aggregation Inhibitors
_xadministration & dosage
650 0 4 _aRenin-Angiotensin System
_xdrug effects
650 0 4 _aTiclopidine
_xadministration & dosage
650 0 4 _aWarfarin
_xadministration & dosage
700 1 _aPirmohamed, M
773 0 _tClinical pharmacology and therapeutics
_gvol. 95
_gno. 3
_gp. 281-93
856 4 0 _uhttps://doi.org/10.1038/clpt.2013.234
_zAvailable from publisher's website
999 _c23352829
_d23352829